The Effects of Atorvastatin Treatment in COPD Patients

Inclusion Criteria: . Written informed consent must be obtained before any assessment is performed. 2. Male and female adults aged ≥40 years, who have signed an Informed Consent Form prior to initiation of any study-related procedure. 3\. Patients with moderate to very severe stable COPD (Stage II-IV) according to the GOLD guidelines. 4\. Patients with a post-bronchodilator FEV1 \< 80% of the predicted normal, and a post-bronchodilator FEV1/FVC \< 0.70 at Visit 1. 5\. Current or ex-smokers who have a smoking history of at least 10 pack years Exclusion criteria 1. Pregnant or nursing (lactating) women 2. Women of child-bearing potential, unless they are using effective methods of contraception during dosing of study treatment. 5. 3. Patients with a clinically significant abnormality at Visit 1. 4\. Patients with a clinically relevant laboratory abnormality at Visit 1 5. Patients with a history of malignancy of any organ system (including lung cancer). 6\. Patients contraindicated for treatment with statins 7. Patients unable to perform acceptable spirometry and lung volumes procedures. 8\. Patients who have had a COPD exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization in the 6 weeks prior to Visit 1. 9\. Patients who have had a respiratory tract infection within 4 weeks prior to Visit 1. 10\. Patients requiring oxygen therapy (\>15 hr/day) on a daily basis for chronic hypoxemia 11. Patients with any history of asthma or onset of symptoms prior to age 40 years. 12\. Patients with concomitant pulmonary disease, (e.g. lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, tuberculosis). 13\. Patients with primary bronchiectasis. 14. Patients with a diagnosis of α-1 anti-trypsin deficiency. 15. Patients with pulmonary lobectomy or lung volume reduction surgery or lung transplantation. 16\. Patients participating in or planning to participate in the active phase of a supervised pulmonary rehabilitation program during the study. 17\. Patients receiving any medications in the class listed in Table 5.1 18. Use of other investigational drugs within 30 days prior to visit 1.